Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors.

Arasanz, Hugo; Morilla, Idoia; Martínez-Aguillo, Maite; Teijeira, Lucía; Vera, Ruth; Alsina, Maria

Arasanz, Hugo; Morilla, Idoia; Martínez-Aguillo, Maite; Teijeira, Lucía; Vera, Ruth; Alsina, Maria.

Afiliación

Arasanz H; Department of Medical Oncology, Hospital Universitario de Navarra, Navarra Medical Research Institute (IdiSNA), Pamplona, Spain.
Morilla I; Oncobiona Group, Navarrabiomed, Navarra Medical Research Institute (IdiSNA), Pamplona, Spain.
Martínez-Aguillo M; Department of Medical Oncology, Hospital Universitario de Navarra, Navarra Medical Research Institute (IdiSNA), Pamplona, Spain.
Teijeira L; Department of Medical Oncology, Hospital Universitario de Navarra, Navarra Medical Research Institute (IdiSNA), Pamplona, Spain.
Vera R; Department of Medical Oncology, Hospital Universitario de Navarra, Navarra Medical Research Institute (IdiSNA), Pamplona, Spain.
Alsina M; Department of Medical Oncology, Hospital Universitario de Navarra, Navarra Medical Research Institute (IdiSNA), Pamplona, Spain.

Transl Lung Cancer Res ; 12(6): 1332-1334, 2023 Jun 30.

Article en En | MEDLINE | ID: mdl-37425415

Palabras clave

Lung cancer; immune-checkpoint; local; oligo-acquired resistance; programmed cell death 1 (PD-1)

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Transl Lung Cancer Res Año: 2023 Tipo del documento: Article País de afiliación: España Pais de publicación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google